- F&P Healthcare reported a net income of NZ$213.0 million for the first half of the year, surpassing analyst estimates of NZ$197.5 million.
- The company declared an interim dividend per share of 19.0 New Zealand cents, which was slightly below the anticipated 20.3 New Zealand cents.
- Operating revenue was reported at NZ$1.09 billion, slightly exceeding the forecasted NZ$1.08 billion.
- Current analyst recommendations include 6 buy ratings, 7 hold ratings, and 4 sell ratings.
A look at Fisher & Paykel Healthcare Corp Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Fisher & Paykel Healthcare Corp, a company specializing in respiratory care and sleep apnea treatment products, has received positive ratings in various aspects of its operations. With a growth score of 4 and a resilience score of 5, the company appears poised for long-term success. These scores indicate strong potential for expansion and ability to weather economic challenges effectively.
Though Fisher & Paykel Healthcare Corp scores lower in value and dividend at 2 each, its momentum score of 4 suggests a promising trajectory. Overall, the company’s focus on innovative healthcare solutions positions it well for sustained growth and market competitiveness.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
